All Patients Enrolled in Sparsentan Trial for FSGS
Photo by Robina Weermeijer on Unsplash

All Patients Enrolled in Sparsentan Trial for FSGS

On November 30, 2020, biopharmaceutical company Travere Therapeutics ("Travere") announced that patient enrollment was complete for the Phase 3 DUPLEX clinical trial. Within the trial, researchers will evaluate the safety,…

Continue Reading All Patients Enrolled in Sparsentan Trial for FSGS
FDA Grants Rare Pediatric Disease Designation for WP1066
GDJ / Pixabay

FDA Grants Rare Pediatric Disease Designation for WP1066

The FDA has recently granted its Rare Pediatric Disease designation to Moleculin's WP1066 for three indications: atypical teratoid rhabdoid tumor, diffuse intrinsic pontine glioma, and medulloblastoma. This designation will aid…

Continue Reading FDA Grants Rare Pediatric Disease Designation for WP1066
Findings From This Phase 2 Idiopathic Pulmonary Fibrosis Trial Look Promising
source: pixabay.com

Findings From This Phase 2 Idiopathic Pulmonary Fibrosis Trial Look Promising

According to a story from GlobeNewswire, the biotechnology company Galecto, Inc., has recently published the results from its phase 2a clinical trial. This study was testing the company's experimental therapy…

Continue Reading Findings From This Phase 2 Idiopathic Pulmonary Fibrosis Trial Look Promising